Castle touts study results for DecisionDx technologies

By staff writers

January 14, 2022 -- Castle Biosciences is touting the results of a study showing that the combined application of its DecisionDx technologies can analyze RNA and DNA from a single biopsy sample for patients with uveal melanoma.

The study, published in Ocular Oncology and Pathology, saw the use of the company's DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq panels.

Out of 105 tumors studied, DecisionDx-UMSeq achieved a positive percent agreement of 100% for detection of both single-nucleotide variants and insertions/deletions (INDELs), with a technical positive predictive value of 98.8% and 100%, respectively.

The company said combining the three technologies showed the highest accuracy for sample analysis.

Castle Biosciences completes Cernostics acquistion
Castle Biosciences has completed its purchase of Cernostics for $30 million. The company will pay up to $50 million more if Cernostics fulfills...
Genomic tests for melanoma in the spotlight
Appropriate use criteria for three gene expression profiling tests used in the management of suspicious pigmented/melanocytic lesions and biopsy-proven...
Castle Biosciences moves ahead with skin cancer test
Castle Biosciences is moving forward with the development of a prognostic gene expression profiling test for cutaneous squamous cell carcinoma. Researchers...

Copyright © 2022

Last Updated ls 1/14/2022 12:01:15 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current